本报道最初发表于Endpoints News。请点击这里查看原文
Summit Therapeutics released a much-anticipated cut of data in North American and European lung cancer patients on Sunday, trumpeting a new analysis in which its drug ivonescimab, when added to chemotherapy, reduced the risk of death by a statistically significant margin compared to chemo alone.
Summit Therapeutics 周日公布了备受期待的北美与欧洲肺癌患者数据，称在一项新分析中，其药物 ivonescimab 联合化疗相比单纯化疗，在统计学上显著降低了死亡风险。
您已阅读5%（421字），剩余95%（7713字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。